The FDA accepts for review Biocryst Pharmaceuticals' (NASDAQ:BCRX) supplemental New Drug Application (sNDA) seeking approval for the use of RAPIVAB (peramivir injection) in pediatric patients. The agency's action date (PDUFA) under Priority Review status is late September.
RAPIVAB was first approved in the U.S. in December 2014 for the treat of uncomplicated influenza in patients at least 18 years old.
Now read: Gilead: The Art Of The Deal »
Subscribe for full text news in your inbox